# US 2023/0248780 A1 · Cell-based gene therapy for neurodegenerative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0248780 A1
- Document ID: US20230248780A1
- Status: Published application
- Kind: A1
- Application number: 18/046,734
- Filed: 2022-10-14
- Published: 2023-08-10
- Earliest claimed: 2018-11-06
- Assignees: ALSaTECH, Inc.
- Applicants: ALSaTECH, Inc.
- Inventors: Claude NICOLAU; Claudine KIEDA; Reynald THINARD; Ruth GREFERATH; Melanie CHEVALIER
- Web page: https://patentgrep.com/patent/US20230248780A1

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2317/50: characterized by immunoglobulin fragments
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/02: containing a signal sequence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates, in part, to cell-based gene therapies, including those targeting, by way of non-limiting example, TDP43 and Aβ aggregates, for the use in neurodegenerative disorders, including without limitation Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease, respectively.

## Claims

### Claim at position 1

-99. (canceled)

### Claim 100

An antibody or antigen binding fragment thereof directed against TDP43 comprising:
(i) a variable heavy domain (VH) comprising:
complementarity-determining region (CDR) 1 having the amino acid sequence of SEQ ID NO: 19,
CDR2 having the amino acid sequence of SEQ ID NO: 20, and
CDR3 having the amino acid sequence of SEQ ID NO: 21; and
(ii) a variable light domain (VL) comprising:
CDR1 having the amino acid sequence of SEQ ID NO: 22,
CDR2 having the amino acid sequence of SEQ ID NO: 23, and
CDR3 having the amino acid sequence of SEQ ID NO: 24.

### Claim 101 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, wherein the antibody or antigen-binding fragment thereof comprises:
(i) a VH having an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO: 13; and
(ii) a VL having an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO: 14.

### Claim 102 (depends on 101)

The antibody or antigen binding fragment thereof of claim 101, wherein the antibody or antigen-binding fragment thereof comprises:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 13; and
(ii) a VL comprising the amino acid sequence of SEQ ID NO: 14.

### Claim 103 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, wherein the antibody or antigen-binding fragment thereof is directed against wild type or mutant human TDP43.

### Claim 104

(canceled)

### Claim 105 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, further comprises a targeting element directed to a neuron.

### Claim 106 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, further comprises a signal peptide having an amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 35.

### Claim 107

(canceled)

### Claim 108 (depends on 100)

A nucleic acid encoding an antibody or antigen binding fragment thereof of claim 100.

### Claim 109 (depends on 108)

An expression vector comprising the isolated nucleic acid of claim 108.

### Claim 110 (depends on 109)

A host cell comprising the expression vector of claim 109.

### Claim 111 (depends on 100)

A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 100 and a pharmaceutically acceptable carrier.

### Claim at position 14

112-117. (canceled)

### Claim 118 (depends on 100)

The antibody or antigen binding fragment thereof of claim 100, wherein the antibody or antigen binding fragment thereof is an anti-TDP43 Fab.

### Claim 119 (depends on 100)

A microvascular endothelial cell (MEC) comprising a nucleic acid encoding the antibody or antigen binding fragment thereof of claim 100, wherein the MEC is engineered to home, traffic, and release the anti-TDP antibody or antigen binding fragment thereof in an organospecific manner.

### Claim 120 (depends on 119)

The MEC of claim 119, wherein the MEC is engineered to home to the brain microvasculature and traffic and release the anti-TDP antibody or antigen binding fragment past the blood brain barrier (BBB).

### Claim 121 (depends on 119)

The MEC of claim 119, wherein the MEC is autologous, and wherein the MEC derived from the bone marrow, the brain, the CNS, the heart, the liver, or the pancreas.

### Claim 122 (depends on 119)

The MEC of claim 119, wherein the nucleic acid comprises a CAG promoter that promotes expression in endothelial cells and/or an insulin sequence that promotes the export of the antibody or antigen binding fragment thereof.

### Claim 123 (depends on 119)

The MEC of claim 119, wherein the antibody or antigen-binding fragment thereof comprises:
(i) a variable heavy chain (VH) having the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 13; and
(ii) a variable light chain (VL) having the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14.

### Claim 124 (depends on 119)

The MEC of claim 119, wherein the antibody or antigen-binding fragment thereof is directed against wild type or mutant human TDP43.

### Claim 125 (depends on 119)

The MEC of claim 119, wherein antibody or antigen binding fragment thereof comprises a targeting element directed to a neuron.

### Claim 126 (depends on 119)

The MEC of claim 119, wherein antibody or antigen binding fragment thereof comprises a signal peptide having an amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 35.

### Claim 127 (depends on 119)

The MEC of claim 119, wherein the antibody or antigen binding fragment thereof is an anti-TDP43 Fab.
